Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Biotech (Nasdaq: MBRX) announced that its abstract has been accepted for a poster presentation at the European Hematology Association (EHA) 2024 Hybrid Congress.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moleculin Biotech (Nasdaq: MBRX) announced that its abstract has been accepted for a poster presentation at the European Hematology Association (EHA) 2024 Hybrid Congress. The event will take place from June 13-16, 2024, in Madrid, Spain, and virtually.
The presentation will focus on the study titled 'Liposomal Annamycin (L-ANN) in Combination with Cytarabine for Treatment of Patients with Acute Myeloid Leukemia (AML) Refractory to or Relapsed After Induction Therapy (MB-106 Study).'
The presenting author will be Dr. Wolfram C. M. Dempke, European Chief Medical Officer of Moleculin.
Positive
- Abstract acceptance at EHA2024 can increase visibility and credibility.
- Presentation focuses on a promising therapy for hard-to-treat AML cases.
- Event participation highlights ongoing clinical research efforts.
Negative
- No new clinical data or trial results were presented in the PR.
- The acceptance of an abstract alone does not imply clinical efficacy or regulatory approval.
Details
News Market Reaction – MBRX
The recorded move for MBRX in the trading session of this news was +2.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Details for the poster presentation are as follows:
Abstract: P537
Session: Acute myeloid leukemia – Clinical
Title: LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) REFACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY (MB-106 STUDY)
Presenting Author: Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin
For more information about the EHA2024 Hybrid Congress, visit the event website.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above are subject to change.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-european-hematology-association-eha-2024-hybrid-congress-302146725.html
SOURCE Moleculin Biotech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.